Supplemental Screening for Women With Extremely Dense Breast Tissue: the DENSE-2 Trial

NCT06636370 · tracked via the Priya Life Science Netherlands tracker

Sponsor

C.H. van Gils

Phase

Not applicable

Started

2024-11-11

Last updated

2026-05-11

Condition(s) studied

Breast Cancer

Investigational drug(s) / intervention(s)

Contrast-enhanced mammography (CEM)Abbreviated MRI (AB-MRI)

Contrast-enhanced mammography (CEM): This intervention group receives supplemental screening with CEM after a negative screening result within the Dutch National Breast Cancer Screening program

Abbreviated MRI (AB-MRI): This intervention group receives supplemental screening with AB-MRI after a negative screening result within the Dutch National Breast Cancer Screening program

Study summary

Women with extremely dense breasts (nearly all glandular and connective tissue, little fatty tissue) have a 3-6 times higher risk of breast cancer than women with very low breast density. Moreover, due to the masking effect of the dense tissue, any breast tumours present are more difficult to detect in these women. With the results of the DENSE trial, the investigators showed that among women with extremely dense breasts, a combination of MRI and mammography could detect tumours earlier than mammography only. As the implementation of MRI in the screening program induces considerable costs and capacity requirements, the Dutch Ministry of Health would like to investigate whether cheaper and acceptable alternatives can be implemented more easily. In the DENSE-2 study, proposed here, we will investigate contrast-enhanced mammography and an abbreviated form of MRI as alternatives, in a large-scale randomized trial, within the current population-based screening program.

Eligibility

Sex

FEMALE

Min age

49 Years

Max age

72 Years

Healthy volunteers

Accepted

Inclusion Criteria: * Participant in the Dutch population-based breast cancer screening program with a negative mammography result (BI-RADS classification 1 or 2). * Extremely dense breast tissue (assessed with Quantra software, category D). * Age between 49-72 years (women are invited to the Dutch screening program in the year they turn 50, so the minimum age is 49 years. The maximum age for inclusion is 72 years to ensure that women can still participate in a second round of supplemental screening). * Living in the service area (travel distance of up to 60 km) of the 15 participating hospitals. * Absence of breast implants (Quantra cannot provide an accurate density determination for breasts with implants). * No objection to data sharing. * Not a participant in the DENSE trial or STREAM trial (participants in the DENSE and STREAM trials are known to the Dutch screening organization). Exclusion Criteria: The additional exclusion criteria for the intervention arms are checked after randomization and recruitment (this order is due to the pre-randomization design): * Presence of in-body metals (only for AB-MRI, this involves specific metals and is asked by telephone). * Previous allergic reaction to the provided contrast agent. * Renal insufficiency (glomerular filtration rate \<30 ml/min) (only for CEM, is checked for with questionnaire I and possibly renal function measurement). * Severe claustrophobia (only for AB-MRI). * Severe obesity (weight \>150 kg) (only for AB-MRI).

Primary outcome measure(s)

Interval Cancer Rate — 0 - 3 year
Measured as a breast cancer diagnosed in between two screening rounds

Trial sites (1)

Facility	City	Region	Status
UMC Utrecht	Utrecht	Netherlands	Recruiting

Other trials for the same condition

Breast Reconstruction and Radiotherapy Recruiting

A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor. Active, not recruiting

Autologous Fat Grafting for Total Breast Reconstruction in Irradiated Breast Cancer Patients Recruiting

Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer Active, not recruiting

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06636370 on ClinicalTrials.gov ↗ ← All trials in the Netherlands